Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



Schizophrenia is a Whole-Body Disease: Examining the Impact of Comorbidities on Morbidity and Mortality

Premiere Date: Wednesday, September 22, 2021

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, September 22, 2022

Faculty


Christoph U. Correll, MDChristoph U. Correll, MD (Moderator)
Professor of Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY
Professor and Chair of the Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany
Investigator, Center for Psychiatric Neuroscience
Feinstein Institute for Medical Research
Manhasset, NY
Medical Director, Recognition and Prevention (RAP) Program
The Zucker Hillside Hospital, Department of Psychiatry
Glen Oaks, NY

Diana O. Perkins, MD, MPHDiana O. Perkins, MD, MPH 
Professor, Department of Psychiatry
Director, (OASIS) Outreach and Support Intervention Services
University of North Carolina School of Medicine
Chapel Hill, NC
Director, Early Psychosis Interventions in North Carolina (EPI-NC)

Statement of Need

Schizophrenia is a clinically complex, multi-system disorder that is associated with an increased incidence of medical comorbidities, complicating management. Overlooked or undermanaged medical comorbidities increase morbidity and all-cause mortality risks. Comprehensive management of medical comorbidities is essential to improve whole patient care and optimize clinical outcomes.

In the first installment of this CME Outfitters Snack series on schizophrenia, faculty experts will provide clinicians with tools to identify and mitigate the impact of medical comorbidities on morbidity and mortality risks.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Employ best practices for the management of patients with schizophrenia at high risk for adverse events.

Financial Support

Supported by an educational grant from Alkermes

Target Audience

Psychiatrists, psychiatric residents, psychiatric nurses, primary care physicians, PAs, nurse practitioners, and pharmacists

Credit Information


ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Correll reports that he receives grants and research support from Janssen Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; Acadia Pharmaceuticals Inc.; Alkermes; Allergan; Angelini Pharma Inc.; Aristo Pharma; Axsome Therapeutics, Inc.; Damitsa; Gedeon Richter; Hikma Pharmaceuticals; IntraCellular Therapies; Janssen Pharmaceuticals, Inc./ Johnson & Johnson; LB Pharmaceuticals.; Lundbeck; Medavante-ProPhase, Inc; MedinCell; Merck & Co., Mitsubishi Tanabe Pharma Corporation; Mylan Pharmaceuticals, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Recordati; Rovi; Servier; Sumitomo Dainippon Pharma Co., Ltd.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A. Inc.; Teva Pharmaceutical Industries Ltd.; and Viatris Inc. He receives royalties from UpToDate.

Dr. Perkins reports that she receives research support from Boehringer-Ingelheim. She is a consultant for Karuna Therapeutics.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

SN-140-092221-64

Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download